title: Infliximab pharmacokinetics in inflammatory bowel disease patients.
abstract: Infliximab, a chimeric monoclonal antibody, has profoundly modified the treatment of several inflammatory diseases, but no satisfactory description of its pharmacokinetics is available. The objective of this study is to describe the pharmacokinetics of infliximab and to explore the sources of its interindividual variability. Thirty-three chronic inflammatory bowel disease patients were studied. Infliximab serum concentrations, obtained during therapeutic drug monitoring, were analyzed using a population approach. Influence of sex, weight, age, concomitant immunosuppressive treatment, and development of antibodies toward infliximab (ATI) on pharmacokinetic parameters was investigated. A two-compartment model with first-order distribution and elimination constants allowed a satisfactory description of infliximab serum concentrations. Mean population distribution and elimination half-lives were 4.3 and 18.5 days, respectively. Weight and sex were found to significantly influence volume of distribution of the central compartment, which increased with weight and was higher in men. Clearance was 2.7 times higher, and elimination half-life was 34% lower in the presence of ATI. In two patients, an increase in infliximab dose or a decrease in dosing interval lead to a decrease in infliximab clearance toward its value in patients without ATI. Infliximab pharmacokinetics are similar to those of other monoclonal antibodies, notably with an elimination half-life of approximately 3 weeks. Both body weight and sex were found to influence infliximab pharmacokinetics, and its clearance increased thrice in the presence of ATI.
authors.affiliation: Université François Rabelais Tours, GICC, Tours, France.
authors.forename: David
authors.initials: D
authors.lastname: Ternant
authors.forename: Alexandre
authors.initials: A
authors.lastname: Aubourg
authors.forename: Charlotte
authors.initials: C
authors.lastname: Magdelaine-Beuzelin
authors.forename: Danielle
authors.initials: D
authors.lastname: Degenne
authors.forename: Hervé
authors.initials: H
authors.lastname: Watier
authors.forename: Laurence
authors.initials: L
authors.lastname: Picon
authors.forename: Gilles
authors.initials: G
authors.lastname: Paintaud
mesh_terms: D000328:Adult; D000465:Algorithms; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000493:pharmacokinetics*; D003627:Data Interpretation, Statistical; D004305:Dose-Response Relationship, Drug; D005260:Female; D006207:Half-Life; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000378:metabolism*; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D011153:Population; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab